Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Merck’s TROP2 ADC extends survival in pivotal cancer trial
Sac-TMT improved overall survival in a phase 3 cancer trial, delivering a second pivotal global win for the TROP2-directed antibody-drug conjugate.
Nick Paul Taylor
Nov 20, 2026 11:20am
Onchilles harnesses new cancer-killing pathway to tackle tumors
Nov 9, 2026 1:30pm
Faeth’s data power oral combo forward in cancer targeted by ADCs
Nov 9, 2026 7:00am
Merck ends Sutro-partnered IL-2 drug in ‘routine prioritization’
Nov 6, 2026 4:20am
AbbVie drops ph. 2 solid tumor drug over ‘limited benefit’
Nov 3, 2026 8:38am
Pfizer trims obesity pipeline, axes phase 2 lung disease asset
Nov 3, 2026 8:02am